BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer

BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer

Mutational activation of KRAS is a common oncogenic event in lung cancer, yet effective therapies are still lacking. Here, we identify B cell lymphoma 6 (BCL6) as a lynchpin in KRAS-driven lung cancer. BCL6 expression was increased upon KRAS activation in lung tumor tissue in mice and was positively...

Full description

Bibliographic Details
Main Authors: Kun Li, Yanan Liu, Yi Ding, Zhengwei Zhang, Juanjuan Feng, Jiaxin Hu, Jiwei Chen, Zhengke Lian, Yiliang Chen, Kewen Hu, Zhi Chen, Zhenyu Cai, Mingyao Liu, Xiufeng Pang
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022-11-01
Series:The Journal of Clinical Investigation
Subjects:
Oncology
Therapeutics
Online Access:https://doi.org/10.1172/JCI161308

Internet

https://doi.org/10.1172/JCI161308

Similar Items